本文报道血清ＨＢＶ复制标志阳性的慢乙肝５４例，随机分为治疗组及对照组各２７例进行ＨＢＩＧ、无环鸟苷、干扰素联合近、远期抗病毒效应观察。治疗组为无环鸟苷第一周按２５～２０ｍｇ／ｋｇ／ｄ计后改１７～１５ｍｇ／ｋｇ／ｄ×５３天，共６０天；人白细胞干扰素１×１０６Ｕ肌注每周３次×４周，后改１．０×１０６Ｕ肌注每周２次×６周，共１０周；ＨＢＩＧ４００Ｕ肌注隔日１次，共１０周，对照组仅给予一般“保肝”药物。其中治疗组１８例，对照组１９例进行治后半年到２年追踪观察，结果近、远期ＨＢｃＡｇ、ＤＮＡＰ、ＨＢＶ－ＤＮＡ阴转率治疗组均高于对照组，其中治疗组近、远期ＨＢｃＡｇ，ＨＢＶ－ＤＮＡ阴转率均达４０％以上，明显高于对照组（Ｐ＜０．０５～０．０１），治疗组近、远期各有４例及２例ＨＢｓＡｇ阴转，而对照组则无一例阴转，从近、远期综合抗病毒效应观察，治疗组全阴率分别为３３．３％、４４．４％，而对照组分别为３．７９％及０％，Ｐ＜０．０１，治疗组无明显毒副反应。对比单用无环鸟苷，全阴率３１．８％；无环鸟苷加干扰素两药联合全阴率３７．５％，均有所提高，达到４４．４％，值得进一步研究。

This paper reported the antiviral effect in 54 cases of chronic hepatits B,who were serum HBVreplication mark positive.It was divided into two groups:the treatment group and the control group in27 cases respoctively.In the treament group,acyclovir was used according to 25-20mg/kg/d in thefirst week,then became to 17-15mg/kg/d for 53 days intravenously;interferon was 1×106U im3/w for 4 weeks,then became to 1×106U im 2/w for 6 weeks;HIBIG was 400U im qod for l0 weeks.It was only treated with cummon protective hepdtic drugs in the control group.18 cases in thetreatment group and l9 cases in the control group had been fullowed-up half to two years;The resultshowed that the negative rate of HBeAg and HBV DNA in the recent and followed-up time reached40%,which was remarkable higher than the control group(P<0.05￣0.0l).4 and 2 cases with HBsAg became negative in the treatment group of different period,and none in the control group.Therecent and followed-up synthetical antiviral effect had observed that the whole negative